The Southampton Paediatric ECMC has particular expertise in early phase immunotherapy and neuroblastoma trials. The centre is leading the MINIvAN trial, an early phase transatlantic immunotherapy study for children with relapsed and refractory neuroblastoma.
Southampton Children’s Hospital covers a population of over 3.7 million, and routinely oversees the care of over 120 new childhood cancer diagnosis a year. We currently have 25 studies open to recruitment, and in the 2019-20 we recuited 62 patients to clinical trials.
University Hospital Southampton NHS Foundation Trust and University of Southampton.
Southampton is the regional paediatric oncology treatment centre for the Wessex region, sharing care with 12 hospitals in Dorset, Hampshire, Surrey and the Channel Islands. It is well served by rail and air links and is able to treat children from across the UK for neuroblastoma / immunotherapy trials. We work closely with our Teenage and Young Adult oncology unit and are able to recruit TYA patients to immunotherapy studies where appropriate.
ECMC, WISH LabLF110 Level FMailpoint 850Southampton General HospitalTremona RoadSouthampton, SO16 6YD
Dr Juliet Gray has a research and clinical interest in neuroblastoma and immunotherapy. She leads a research group with the Southampton Centre for Cancer Immunology, and has leadership roles in a number of international neuroblastoma trials. She is chair of the NCRI Neuroblastoma subgroup and the European Research Network (SIOPEN) Clinical Trials Committee, and a member of the NCRI Children’s Group and CRUK Protocol Safety Review Board.
We have expertise in both solid tumours and haematological malignancies.
We have expertise pre-clinical, translational and clinical expertise in immunotherapy and neuroblastoma, including preclinical modelling and assessment of novel immunotherapies and developing validated immune end points for clinical trials.
The MINivAN trial is looking at combining mIBG, nivolumab and dinutuximab beta to treat neuroblastoma that has continued to grow during treatment or came back after treatment.
For some children and young people their neuroblastoma is cured by the first treatment they have. But for others, their neuroblastoma continues to grow during treatment or comes back after it. Researchers are looking for new ways to treat these children and young people.
In this study they are looking at 3 treatments:
In this study the researchers are looking at combining these 3 treatments. The main aim of the study is to find out:
This is an international study. The team need about 36 people to join worldwide with 12 people from the UK.
In the UK you have mIBG at University Colege London Hospital (UCLH). In the UK you have nivolumab and dinutuximab beta at Southampton Children's Hospital.
The Chief Investigator of this study is Dr Juliet Gray
